JR Rahn, Mindmed Co-Founder and Board Member

Mindmed Acquires Opioid Addiction Drug Candidate Based on the Natural Psychedelic Ibogaine



TORONTO, Sept. 16, 2019 /PRNewswire/ — Mind Medicine, Inc. (“Mindmed”), the leading neuro-pharmaceutical company focused on discovering and developing medicines based on psychedelics, has finalized the acquisition of the 18-MC drug development program, an anti-addictive molecule that was previously funded by the National Institute on Drug Abuse (“NIDA”). Mindmed acquired the project from Savant HWP Inc., whose leadership team of top researchers and drug developers will also ...

Continue Reading →